Everard G.B. Vijverberg

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Catherine J. Mummery, Anne Börjesson‐Hanson, D. Blackburn et al. · Nature Medicine · 2023 · 318 citations · Full text

Life Sciences, Neurology, Neuroscience +17

The Alzheimer’s disease drug development landscape

Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt et al. · Alzheimer s Research & Therapy · 2021 · 137 citations · Full text

Medicine, Neurology, Pharmacology +17

Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface

Lisa Vermunt, Marco Otte, Inge M.W. Verberk et al. · Annals of Clinical and Translational Neurology · 2022 · 131 citations · Full text

Medicine, Neurology, Neuroscience +17

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum

Lieke Meeter, Everard G.B. Vijverberg, Marta del Campo et al. · Neurology · 2018 · 128 citations · Full text

Medicine, Neurology, Neuroscience +17

Diagnostic Accuracy of MRI and Additional [ ¹⁸ F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes

Everard G.B. Vijverberg, Mike P. Wattjes, Annemiek Dols et al. · Journal of Alzheimer s Disease · 2016 · 93 citations · Full text

Medicine, Neurology, Psychiatry +17